| Zacks Company Profile for GlaxoSmithKline plc (GSK : NYSE) |
|
|
| |
| • Company Description |
| Glaxo has 3 core businesses - Pharmaceuticals, Vaccines and Consumer Healthcare. The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. In August 2019, Glaxo and Pfizer merged their consumer healthcare unit into a new JV. Glaxo owns a controlling stake in the JV. Glaxo plans to split itself into two standalone companies. The new Glaxo will be a biopharma company. Glaxo intends to separate its Consumer Healthcare segment into a standalone company in 2022. The independent Consumer Healthcare company will be named Haleon. In 2015, Glaxo divested two quadrivalent meningitis ACWY vaccines ' Nimenrix and Mencevax ' to Pfizer, a portfolio of OTC brands to Perrigo, and all its remaining rights to Arzerra for auto-immune indications including multiple sclerosis to Novartis. In January 2019, Glaxo acquired Tesaro, an oncology focused biotech company, which added the PARP inhibitor Zejula to its portfolio.
Number of Employees: 90,096 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $44.52 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 5,541,051 shares |
| Shares Outstanding: 2,541.79 (millions) |
| Market Capitalization: $113,160.72 (millions) |
| Beta: 0.64 |
| 52 Week High: $46.97 |
| 52 Week Low: $37.80 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-0.78% |
8.64% |
| 12 Week |
4.31% |
17.23% |
| Year To Date |
0.95% |
23.33% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Emma Walmsley - Chief Executive Officer
Jonathan Symonds - Chairman
Iain Mackay - Chief Financial Officer
Charles Bancroft - Director
Vindi Banga - Director
|
|
Peer Information
GlaxoSmithKline plc (AGN.)
GlaxoSmithKline plc (ABBV)
GlaxoSmithKline plc (NVO)
GlaxoSmithKline plc (LLY)
GlaxoSmithKline plc (RHHBY)
GlaxoSmithKline plc (JNJ)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 37733W105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
|
|
Share - Related Items
Shares Outstanding: 2,541.79
Most Recent Split Date: 11.00 (2.00:1)
Beta: 0.64
Market Capitalization: $113,160.72 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 3.07% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.68 |
Indicated Annual Dividend: $1.37 |
| Current Fiscal Year EPS Consensus Estimate: $3.18 |
Payout Ratio: 0.71 |
| Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: 0.02 |
| Estmated Long-Term EPS Growth Rate: 7.07% |
Last Dividend Paid: 05/19/2022 - $0.94 |
| Next EPS Report Date: 07/27/22 |
|
|
|
| |
